ReleaseWire

Axium Healthcare Pharmacy, one of the nation’s largest independent specialty pharmacy providers, announced today that it has been selected as the 2011 SMART Awards recipient in the Healthcare & Life Sciences category by the Orlando Chapter of the Association for Corporate Growth (ACG Orlando).

Dr. Reddy’s Laboratories (NYSE: RDY) and Alchemia Limited, Brisbane, Australia (ASX: ACL) announced today that Dr. Reddy’s has received final approval of Dr. Reddy’s ANDA for Fondaparinux Sodium Injection, a bioequivalent generic version of Arixtra, in the US market on July 11, 2011 by the United States Food & Drug Administration (USFDA). The approval covers 2.5 mg/ 0.5 mL, 5.0 mg/ 0.4 mL, 7.5 mg/ 0.6 mL and 10 mg/ 0.8 mL doses of the drug in prefilled color-coded, single-dose syringes with automatic needle safety device. Dr. Reddy’s will manufacture fondaparinux under license using a patented process developed by Alchemia.

GBI Research’s report, “Active Pharmaceutical Ingredients (API) Market in Asia-Pacific to 2016 – The Merchant Market for Generics Continues to Grow as the Competition Increases” provides detailed insight into the Asia-Pacific API market.

This analysis examines the historical and forecast performance for GlaxoSmithKline in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

GBI Research’s report, “Active Pharmaceutical Ingredients (API) Market in Asia-Pacific to 2016 - The Merchant Market for Generics Continues to Grow as the Competition Increases” provides detailed insight into the Asia-Pacific API market. The research presents detailed analysis and forecasts of the major economic and market trends affecting the API markets in this region. The report contains market forecasts, product type analysis, drivers and restraints, and competitive landscape of major producers in the region. In addition, it includes market forecasts, product type analysis, therapeutic categories analysis and SWOT analysis of the API markets in the major countries of the region. Overall, the report presents a comprehensive analysis of the Asia-Pacific API market, covering all the major parameters. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

TechNavio analysts forecast that the Global Drug Eluting Stents market will reach $5.7 Billion in 2014. One of the key factors contributing to this market’s growth is the ability of these stents to lower the rate of restenosis. However, the commercialization of bio-absorbable stents could pose a challenge to the growth of this market.

Datamonitor’s Report “AstraZeneca: PharmaVitae Profile” is now available at ReportsnReports.com.

This report is the result of an extensive survey drawn from ICD Research’s exclusive panel of leading pharmaceutical industry executives. It analyzes how pharmaceutical companies’ procurement expenditure, business strategies and practices are set to change in 2011–2012. This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also identifies future growth of buyers and suppliers, M&A and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes.

Frontline is the veterinary recommended non-prescription flea treatment for both dogs and cats. Frontline Flea Treatment contains the active ingredient Fipronil. Frontline for Cats is available in packs of 3 or 6 pipettes and Frontline for dogs is available in 3 or 6 pipettes for the different weight bands (2-10kg, 10-20kg, 20-40kg & 40-60kg). Frontline Flea Control for Dogs can be used in puppies from 8 weeks of age and weighing over 2kg. Frontline Flea Cats can be used in kitten from 8 weeks of age and weighing at least 1kg.

Nancy McFarlane, president of MedPro Rx, Inc., a provider of specialty pharmacy services to clients with chronic illnesses who need clotting factor and IVIg, announced that the pharmacy was named the No. 1 small business in the Triangle in the Top 300 Small Businesses of the South competition, hosted by Business Leader magazine.

The IAPAM has trained over 350 physicians on how to safely offer hCG for weight loss, and over 10,000 patients have successfully lost weight using the IAPAM's Exclusive hCG Protocol.

The Indian obesity drug market is estimated to be worth INR 25 Billion in 2011, says a new research report from RNCOS.

MedPro Rx, Inc. (medprorx.com), a provider of specialty pharmacy services to clients with chronic illnesses who need clotting factor, IVIg and other medication, has announced that it has applied for Specialty Pharmacy Accreditation from URAC, a Washington, D.C.-based health care accrediting organization that establishes quality standards for the health care industry. URAC offers the only third-party, voluntary accreditation program of this scope for pharmacy benefit management and prescription services industry. All standards were developed by URAC’s Pharmacy Advisory Committee, which includes a wide range of stakeholders: employers, consumers, pharmacy consultants, health plans, retail pharmacy, pharmacy benefit management organizations, pharmacy professional organizations; labor, and large public purchasing groups.

According to our latest research offering “Russian Pharma Sector Forecast to 2013”, the Russian pharmaceutical industry will ride the success of parapharmaceuticals segment and will grow at a CAGR of around 13% during 2011-2013. Although not registered as pharmaceutical drugs, the products in this segment are utilized for the maintenance and improvement of health. The major sub-segments in this category include vitamins, minerals, tonics, syrups, and curative cosmetics, such as ointments, gels, liniments, etc. Rising demand for these products can be attributed to the increasing disposable income of the people and rising health & beauty consciousness.

The announcement comes on the heels of the FDA’s approval of Merck’s VictrelisTM and Vertex’s IncivekTM. Both drugs are approved for use in combination with peg interferon and ribavirin, creating a triple therapy regimen. Clinical trials have shown that using one of the two new drugs along with peg interferon and ribavirin drugs is more effective at producing a sustained virological response (SVR).

Cleaning out the medicine cabinet? Not sure what to do about the unused, outdated, or unwanted medications you find? Kerr Drug, a leading provider of pharmacy and other healthcare related services, is offering a new solution. The specially designed TakeAway Environmental Return System Envelopes, made by Sharps Compliance Corporation, will be available at all Kerr Drug stores throughout North Carolina starting May 23rd. The envelopes sell for $3.99. The system offers Kerr Drug customers a safe and convenient way to dispose of non-controlled prescription or over-the-counter (OTC) medications.

There are no genetic tests, no brain scans, blood tests, chemical imbalance tests or X-rays that can scientifically/medically prove that any psychiatric label is a real medical condition.

Backed by factors, such as high investments and innovative drug R&D mechanisms, the global pharmaceutical market will grow at a CAGR of 6.5% during 2011-2013, RNCOS identified.

Biopharmaceutical and chemical companies are under pressure to develop scalable crystallization processes faster—at lower costs and with higher quality.

Revenue generated by the UK generics market is anticipated to grow at a CAGR of over 16% during 2011 - 2013, says a new research report from RNCOS.

The Middle East & African pharma industry is experiencing tremendous growth due to the introduction of industry friendly regulations, and is expected to grow at a stupendous CAGR of 12.4% during 2011-2013, says RNCOS.

Factors like rising awareness level and government support will lead Japanese generics market to grow at a CAGR of 8% during 2009-2013.

The global contract manufacturing market is expected to grow at a tremendous CAGR of 11% during 2011-2013, says RNCOS in its new research report.

AFFY Pharma Private Limited, We are a renowned name in pharmaceutical industry that manufactures formulated medicated products, soft gelatin capsules.